Chenguang Biotech announced that in the first half of 2026, the company expects to achieve net profit attributable to shareholders of listed companies of 177 million yuan to 190 million yuan, a year-on-year decrease of 17.66% to 11.62%; net profit after deducting non-recurring profit and loss of 161 million yuan to 174 million yuan, a year-on-year decrease of 12.72% to 5.68%. The decline in performance was due to a year-on-year decline in sales of pigment products and revenue from the cottonseed business in the plant extract business, and a decrease in investment income due to the decline in the performance of participating companies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.